|
2024
|
Invention
|
Priming of cancer cells with low dose naltrexone.
The disclosure provides methods of treating a ... |
|
2023
|
Invention
|
Treatment of cancer with naltrexone.
The present invention provides novel therapeutic applicatio... |
|
|
Invention
|
Autoimmune therapy.
The present invention relates to naltrexone or an analogue thereof, wherein ... |
|
|
Invention
|
Assay to identify anti-cancer agents.
An in vitro method for identifying an anti-cancer agent, t... |
|
2022
|
Invention
|
Naltrexone for boosting the therapeutic utilty of 5-ht receptor agonists.
A single unit oral dos... |
|
|
Invention
|
Naltrexone for improving the effectiveness of 5-ht receptor subtype 2a, 2b or 2c agonists.
A com... |
|
|
Invention
|
Compositions comprising an agonist of 5-hydroxytryptamine (5-ht) receptor subtype 3.
A compositi... |
|
|
Invention
|
Treatment for autoimmune diseases.
A pharmaceutical composition comprising naltrexone or a metab... |
|
|
Invention
|
Naltrexone for boosting the therapeutic utility of 5-ht receptor agonists. A single unit oral dos... |
|
|
Invention
|
Treatment for autoimmune diseases. A pharmaceutical composition comprising naltrexone or a metabo... |
|
|
Invention
|
Compositions comprising an agonist of 5-hydroxytryptamine (5-ht) receptor subtype 3. A compositio... |
|
|
Invention
|
Naltrexone for improving the effectiveness of 5-ht receptor subtype 2a, 2b or 2c agonists. A comp... |
|
|
Invention
|
Treatment for autoimmune disease. The present invention is based on the finding that the inhibiti... |
|
|
Invention
|
Naltrexone compositions.
The invention is a single unit oral dose pharmaceutical composition com... |
|
|
Invention
|
Naltrexone compositions. The invention is a single unit oral dose pharmaceutical composition comp... |
|
2021
|
Invention
|
Priming of cancer cells with low dose naltrexone. The disclosure provides methods of treating a t... |
|
2020
|
Invention
|
Cancer treatment comprising naltrexone and a cannabinoid.
The present invention is based on the ... |
|
|
Invention
|
Cancer treatment comprising naltrexone and a cannabinoid. The present invention is based on the f... |
|
|
Invention
|
Method for determining efficacy.
The invention relates to a method for monitoring the treatment ... |
|
|
Invention
|
Method of monitoring treatment.
The invention relates to a method for monitoring the treatment o... |
|
|
Invention
|
Method of monitoring treatment. The invention relates to a method for monitoring the treatment of... |
|
|
Invention
|
Method for determining efficacy. The invention relates to a method for monitoring the treatment o... |
|
2019
|
Invention
|
Autoimmune therapy. The present invention relates to naltrexone or an analogue thereof, wherein t... |
|
2018
|
Invention
|
Cancer treatment. The present invention is based on the finding that the inhibition of the prolif... |
|
|
Invention
|
Assay to identify anti-cancer agents. wherein the therapeutic efficacy of the target anti-cancer ... |
|
|
Invention
|
Agent that increases the expression of the bcl2-associated agonist of cell death for the treatmen... |
|
|
Invention
|
Combination for use in the treatment of lung cancer. The invention is based on the finding that c... |
|
|
Invention
|
Agent that increases the expression of the opioid kappa 1 for the treatment of cancer. It has bee... |
|
|
Invention
|
A combination for use in the treatment of lung cancer. The invention is based on the finding that... |
|
|
Invention
|
Assay to identify anti-cancer agents. An in vitro method for identifying an anti-cancer agent, th... |
|
|
Invention
|
An agent that increases the expression of the opioid kappa 1 for the treatment of cancer. It has ... |
|
|
Invention
|
An agent that increases the expression of the bcl2-associated agonist of cell death for the treat... |
